Clinical trials: Influenza in Humans
Flu
PET-CT Scans in Healthy Volunteers After Flu Vaccination
This study is being done to learn how previous flu vaccination or previous infection with flu virus affects the immune response to vaccination.
- Trial name
- Pro00000226 (NCT00769002)
- Testing
- FluShield, FluShield - same arm, FluShield - opposite arm
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Influenza, Human
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the…
- Trial name
- NCT00545532
- Testing
- oseltamivir
- Where
- 208 sites in United States, Argentina and 24 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Influenza
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched control subjects .
- Trial name
- NCT01436370
- Testing
- Trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00964158
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously…
- Trial name
- NCT00506350
- Testing
- Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose, Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Self-Administered Nasal Influenza Feasibility Study
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to…
- Trial name
- SNIF (NCT01933048)
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 1,077 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Healthy
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.
- Trial name
- NCT00877448
- Testing
- Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza, COVID-19
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
- Trial name
- NCT06020118
- Testing
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Where
- 8 sites in United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of Fluviral™ containing the influenza strains recommended for the 2013-2014 season in adults aged 18 years and older.
- Trial name
- NCT01878825
- Testing
- Fluviral™
- Where
- Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Refusal
Promoting Altruism to Enhance Vaccine Acceptance
Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local…
- Trial name
- NCT04568590
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Influenza, Seasonal Influenza
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and sometimes the lungs. Vaccines are given to teach the body to prevent or fight infection.
- Trial name
- NCT04896086
- Testing
- VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adolescent HPV Vaccine, Adolescent Influenza Vaccine
4 Pillars Toolkit for Adolescent Vaccination
The purpose of this study is to test whether or not the 4 Pillars Immunization Toolkit increases adolescent vaccination rates, particularly influenza and human papillomavirus (HPV) but also tetanus, diphtheria and pertussis…
- Trial name
- NCT02165722
- Testing
- 4 Pillars Toolkit
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Influenza, Human
Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza
This research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza.
- Trial name
- NCT03410862
- Testing
- Elderberry Extract
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- michael macknin
Influenza
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.
- Trial name
- NCT01051661
- Testing
- GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
- Where
- 17 sites in Australia, Brazil and 6 more
- Volunteers
- 6,154 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Efficacy Study With QIVc in Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age.
- Trial name
- NCT03932682
- Testing
- QIVc, Comparator
- Where
- 74 sites in Bangladesh, Bulgaria and 13 more
- Volunteers
- 5,723 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
High-risk Influenza Vaccine Alert
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of salient alerts in the electronic health record that indicate a patient's high risk for flu and its complications.
- Trial name
- NCT05492786
- Testing
- Alert, Salient alert features, High-risk Text
- Where
- United States
- Volunteers
- 80,452 people
- Sponsor
- Geisinger Clinic
Influenza
Home Administration of FluMist by Parents/Caregivers
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical…
- Trial name
- NCT01938170
- Testing
- FluMist
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza
Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women
The purpose of this research study is to learn more about the safety of 2 licensed flu vaccines, nasal spray and flu vaccine shot, in mothers and their infants, when given to women who are breastfeeding and to compare the immune…
- Trial name
- NCT01181323
- Testing
- Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
- Where
- 6 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to < 60 months of age, with 28-day shedding follow-up and 180-day safety…
- Trial name
- NCT00344305
- Testing
- Trivalent influenza virus vaccine live, intranasal
- Where
- 16 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC